Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

AMGEN INC.

(AMGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about AMGEN INC.
11:38aEnterprise software firm Informatica valued at $7.5 bln in stock market return
RE
10/26Building Healthcare System Resilience With Biosimilars
PU
10/26Fortune and Great Place to Work« Name Amgen One of the World's Best Workplaces™ i..
PR
10/25ANALYSIS : Capitol Hill drug pricing reform opponents among the biggest beneficiaries of p..
RE
10/21AMGEN : Keeps Quarterly Dividend at $1.76 a Share, Payable Dec. 8 to Stockholders of Recor..
MT
10/21AMGEN : Announces 2021 Fourth Quarter Dividend
PR
10/21Amgen Inc. Declares Dividend for the Fourth Quarter of 2021, Payable on December 8, 202..
CI
10/21AMGEN : Introducing Undruggable, a New Serial Podcast from Amgen R&D Exploring how Multisp..
PU
10/20AMGEN : A Special Edition of Innovation2, brought to you by David and Jim Reese (Brothers2..
PU
10/20CARLYLE : Venture Funds Invest Up to $430 Million in Saama Technologies
MT
10/19AMGEN : Completes Teneobio Acquisition
MT
10/19AMGEN : Successfully Completes Acquisition Of Teneobio, Inc.
PR
10/19AMGEN : Named One of the ‘World's Best Workplaces'
PU
10/19Amgen Inc. completed the acquisition of TeneoBio, Inc. from Lightspeed Ventures, LLC an..
CI
10/18AMGEN : Third-Longest Tenured Employee Leaves a Legacy After 35 Years of Service
PU
10/18AMGEN : “Green” Chemistry Makes Pharmaceutical Manufacturing Better for the Pl..
PU
10/18AMGEN : Software firm Informatica eyes $9 bln valuation in stock market return
RE
10/15Analysis-Deals, data buzz could help biotech shares exit Wall St's 'no man's land'
RE
10/15Deals, data buzz could help biotech shares exit Wall St's 'no man's land'
RE
10/13LUYE PHARMA : Chinese Regulators Accept Luye Pharma's Marketing Authorization for Osteopor..
MT
10/12AMGEN : Morgan Stanley Adjusts Amgen PT $235 from $251, Keeps Equalweight Rating
MT
10/11AMGEN : Working Together to Improve Public Health Outcomes
PU
10/08ADRs Close Higher; Oil Majors Trade Actively
DJ
10/08AMGEN : Discover What Fosters Innovation and Drives Change Through Amgen's Innovation2 Ser..
PU
10/08ASTRAZENECA : Gets US FDA's Orphan Drug Designation for Eosinophilic Esophagitis Drug
MT
10/08ASTRAZENECA : Tezepelumab Gets FDA Orphan Designation for Eosinophilic Esophagitis
DJ
10/07AMGEN : Announces New LUMAKRAS™ (sotorasib) Combination Data From Phase 1b CodeBreaK..
PR
10/07Amgen Announces New LUMAKRASÖ Combination Data From Phase 1b CodeBreaK 101 Study In Pat..
CI
10/07AMGEN : Working With Neumora Therapeutics to Develop Therapeutics for Brain Diseases
MT
10/07AMGEN : and Neumora Therapeutics Announce Strategic R&D Collaboration to Accelerate Novel ..
PR
10/07Amgen and Neumora Therapeutics Announce Strategic R&D Collaboration to Accelerate Novel..
CI
10/07Neumora announced that it has received $500 million in funding from a group of investor..
CI
10/05Amgen's 'Underappreciated' Inflammation Portfolio Set to Trigger Growth, RBC Capital An..
MT
10/04AMGEN : Presentation on Inflammation Portfolio from EADV
PU
10/02Kyowa Kirin and Amgen Present Positive Late-Breaking Data from Phase 2 Study of KHK4083..
CI
10/01GLOBAL DIVERSITY AWARENESS MONTH : Our Differences Lead to Better Science
PU
09/29AMGEN : To Webcast Investor Call At EADV 2021
PR
09/28CANDID CONVERSATIONS : Amgen Latin Employee Network
PU
09/28AMGEN : U.S. FDA approves AbbVie's migraine prevention drug
RE
09/28AMGEN : U.S. FDA approves AbbVie's migraine prevention drug
RE
09/27AMGEN : Exploring Climate Change and Lung Health
PU
09/27AMGEN : Secures FDA's Approval for Repatha in Heterozygous Familial Hypercholesterolemia
MT
09/24Amgen Announces U.S. Food and Drug Administration Approves Repatha in Pediatric Patient..
CI
09/24AMGEN : FDA Approves Repatha« (evolocumab) In Pediatric Patients Age 10 And Older With Het..
PR
09/24FDA APPROVES AMGEN'S REPATHA AS ADD- : Bloomberg
MT
09/24Amplitude Healthcare Acquisition Corporation announced that it has received $100 millio..
CI
09/23WALL STREET STOCK EXCHANGE : As smooth as silk
09/23AMGEN : Daiwa Securities Downgrades Amgen to Neutral From Outperform, Price Target at $220
MT
09/23ANALYST RECOMMENDATIONS : Amgen, Apple, AstraZeneca, FedEx, T-Mobile US...
09/22AMGEN : To Present At The 2021 Cantor Global Healthcare Conference
PR
09/22AMGEN : Releases 8th Edition of Biosimilar Trends Report
PR
09/22AMGEN : Investor Presentation September 2021
PU
09/21AMGEN : Margaret Chu-Moyer Honored with Prestigious Portoghese Lectureship
PU
09/21AMGEN : Secures Favorable Ruling in Patent Dispute Against Sandoz, Zydus Over Psoriasis Dr..
MT
09/20AMGEN : Wins Patent Case on Otezla« (apremilast)
PR
09/20AMGEN : Joins International Respiratory Coalition as Founding Member
PU
09/20VERASTEM : Amgen to Evaluate VS-6766, Sotorasib Combo Therapy in Non-Small Cell Lung Cance..
MT
09/20Wall Street Futures Tumble as China's Evergrande Default Risk Weighs on Sentiment
MT
09/20VERASTEM : Health Care
MT
09/20US Futures Fall, China's Evergrande Default Risk Weighs on Sentiment
MT
09/20Top Premarket Gainers
MT
09/20Verastem Oncology and Amgen Partner to Evaluate VS-6766 in Combination with LUMAKRASTM ..
CI
09/20Verastem Oncology in Collaboration Agreement With Amgen
DJ
09/19MIRATI THERAPEUTICS : drug combination shrinks tumors in 39% of colon cancer patients in s..
RE
09/17AMGEN : Celebrates 20 Years of Aranesp« (darbepoetin alfa) as a Treatment for Patients Wit..
PU
09/16AMGEN : Diversity, Inclusion and Belonging at Amgen – A Progress Report
PU
09/16AMGEN : Enters Collaboration With Boehringer Ingelheim to Study Drug Combination to Treat ..
MT
09/16AMGEN : Conference Call from ESMO Presentation
PU
09/16AMGEN : Says Colorectal Cancer Drug Combination Safe and Effective in Trial
MT
09/16AMGEN : LUMAKRAS™ (Sotorasib) Combined With Vectibix« (Panitumumab) Showed Encouragi..
PR
09/16Amgen Inc. Announces the First Combination Study Results from the Phase 1B/2 Codebreak ..
CI
09/15China's biotech sector comes of age with big licensing deals, global ambitions
RE
09/14AMGEN : And The Lundquist Institute Announce That Diadem Therapeuctics Will Receive The Fi..
PR
09/14INSIDER BUY : Beigene
MT
09/14Health Canada Approves Amgen's LUMAKRASÖ, the First and Only Targeted Treatment for Pat..
CI
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on AMGEN INC.